[68Ga]Ga-PSMA-11 PET/CT与前列腺癌骨转移:现有标准化标准的诊断效能
该研究回顾性分析118例因初始分期或复发评估行[68Ga]Ga-PSMA-11 PET/CT的前列腺癌患者,按PSMA-RADS和PROMISE标准判读骨病变,以既往或随访检查组合为参考标准。共识别265个骨异常,148个(55.8%)为PSMA-RADS-3B;序贯联合两种标准可将不确定病变从147个降至2个,灵敏度89.3%、特异度96.6%。作者认为PSMA-RADS-3B且PROMISE阳性者应高度提示恶性。
要点
- 265个骨异常中148个(55.8%)为PSMA-RADS-3B,不确定病变约占PSMA PET所见骨病变近半。
- PSMA-RADS-3B截点灵敏度100%、特异度63.6%;PSMA-RADS-4截点灵敏度40.5%、特异度100%。
- 序贯PSMA-RADS/PROMISE法使不确定病变从147个降至2个,灵敏度89.3%、特异度96.6%。
核心结论
- [68Ga]Ga-PSMA-11 PET/CT诊断骨转移准确性高,但不确定病变约占PSMA PET所见骨病变近半。
- 序贯联合PSMA-RADS与PROMISE标准可减少被判为不确定的病变数量。
- 作者认为,PSMA-RADS-3B且按PROMISE标准判为阳性的病变应视为高度提示恶性。
研究设计与样本
- 回顾性分析118例因初始分期或复发评估行[68Ga]Ga-PSMA-11 PET/CT的前列腺癌患者。
- 病变按PSMA-RADS和PROMISE标准判读,记录每个病变的SUVmax和位置。
- 以既往或随访检查的组合作为参考标准区分良恶性病变。
主要发现
- 118例患者中70例共识别265个骨异常,其中50例(42.4%)患者的148个(55.8%)病变为PSMA-RADS-3B,本队列无PSMA-RADS-3D病变。
- 不确定病变最常见于肋骨(30.6%),其次为骨盆(26.5%);肋骨不确定摄取中恶性占33.3%,骨盆占66.7%。
- 最终诊断与SUVmax、前列腺特异性抗原(PSA)、PSA倍增时间、国际泌尿病理学会(ISUP)评分及病灶数量显著相关。
- PSMA-RADS-3B截点灵敏度100%、特异度63.6%;PSMA-RADS-4截点灵敏度40.5%、特异度100%。
- PROMISE标准与序贯PSMA-RADS/PROMISE策略灵敏度均为89.3%、特异度均为96.6%;序贯法将不确定病变从147个降至2个。
关键数值与推荐
- PSMA-RADS-3B截点:灵敏度100%、特异度63.6%。
- PSMA-RADS-4截点:灵敏度40.5%、特异度100%。
- PROMISE标准:灵敏度89.3%、特异度96.6%。
- 序贯PSMA-RADS/PROMISE策略:灵敏度89.3%、特异度96.6%,不确定病变从147个降至2个。
- PSMA-RADS-3B病变中恶性占53%;序贯法阳性病变中真阳性占95.5%、假阴性占32.6%。
临床怎么用
- 作者认为,PSMA-RADS-3B且按PROMISE标准判为阳性的病变应视为高度提示恶性。
- 序贯联合PSMA-RADS与PROMISE标准可减少被判为不确定的骨病变数量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In up to two thirds of prostate-specific membrane antigen (PSMA) PET scans, unspecific bone uptake has been described. The aim of this study was to estimate the diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT for bone metastases and the occurrence of equivocal lesions. Methods: We analyzed retrospectively 118 patients who underwent a [68Ga]Ga-PSMA-11 PET/CT for initial staging or recurrence evaluation. Lesions were interpreted according to the PSMA reporting and data system (PSMA-RADS) and the prostate cancer molecular imaging standardized evaluation (PROMISE) criteria. The SUVmax and the localization of each lesion were recorded. A combination of prior or follow-up examinations was used as a reference standard to categorize benign and malignant lesions. Correlation between the final diagnosis and imaging or clinicobiochemical parameters was tested. The diagnostic accuracy was calculated for different cutoffs of PSMA-RADS criteria, for PROMISE criteria, and the sequential combination of both. Results: In total, 265 bone abnormalities were identified in 70 of 118 patients. Among these, 148 (55.8%) lesions in 50 (42.4%) patients were classified as PSMA-RADS-3B. There were no PSMA-RADS-3D lesions in our cohort. Equivocal lesions were more frequent on the ribs (30.6%) followed by the pelvis (26.5%), but in the ribs, such an uptake was malignant in 33.3% of cases versus 66.7% in the pelvis. A significant association was found between the final diagnosis and the SUVmax, prostate-specific antigen (PSA), PSA doubling time, International Society of Urological Pathology score, and the number of foci. The sensitivity and specificity were 100% and 63.6% for the PSMA-RADS-3B cutoff, respectively; 40.5% and 100% for the PSMA-RADS-4 cutoff, respectively; and 89.3% and 96.6% for both the PROMISE criteria and the sequential PSMA-RADS/PROMISE strategy, respectively. In the sequential method, the number of equivocal lesions was reduced from 147 to 2. We found that 53% of PSMA-RADS-3B lesions were malignant; 95.5% of lesions classified positive by the sequential method were true positives, whereas 32.6% were false negatives. Conclusion: [68Ga]Ga-PSMA-11 PET/CT has high accuracy for the diagnosis of bone metastases. Equivocal lesions constitute nearly half of the lesions seen on PSMA PET. The sequential combination of PSMA-RADS and PROMISE criteria reduces the number of lesions classified as equivocal. PSMA-RADS-3B lesions which are positive according to the PROMISE criteria should be considered highly suggestive of malignancy.
引用
- Mainta IC, Neroladaki A, Wolf NB, et al. [68Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria. J Nucl Med. 2024. PMID: 39117453. doi:10.2967/jnumed.124.267899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。